Perspectives on Enquiry & Evidence

Cytel's blog featuring the latest industry insights.

Featured post

Aligning Clinical Trial Design with Investment Priorities

When working with investors, it’s critical that drug and device developers consider how their clinical trial design aligns with investment priorities. Natalia Muehlemann and Ari Brettman (Blackstone Life Sciences) discuss what investors look for when evaluating clinical development programs, and the value of simulation-guided design in informing decisions and facilitating communication with investors.

Read full article

Perspectives on Enquiry and Evidence

January 26, 2021

Cytel Thought Leadership on Power of Bayesian Methods

Bayesian models offer a flexible way of incorporating historical controls in the analysis of trial data (whether single...

Read article

October 12, 2020

Bayesian Statistics and FDA Regulatory Acceptability

Cytel and Novartis are together hosting a complimentary Bayesian Virtual Symposium and an Interactive 7-part workshop....

Read article

October 5, 2020

The Meta-Analytic-Predictive Priors Generation and Comparisons

Staying abreast of the rapid pace of clinical development means adopting innovative or computationally intensive...

Read article

September 30, 2020

A Virtual Event Brought to you by Cytel and Novartis on Innovations

Today, there is a need for advanced quantitative techniques to combine all available information for better decision...

Read article